Finance

Lists
Q3 2026 earnings • in 4 days
See details
KYNB:NASDAQ
Kyntra Bio Inc
$3.79
-4.39%
(-0.17) 1D
Nov 5, 11:07:04 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KYNB...
Open
$3.96
High
$4.14
Low
$3.72
Mkt. cap
15.33M
Avg. vol.
22.49K
Volume
4.78K
P/E ratio
0.08
52-wk high
$9.70
52-wk low
$3.72
EPS
$45.30
Beta
1.08
Shares outstanding
4.05M
No. of employees
34
Open
$3.96
High
$4.14
Low
$3.72
Mkt. cap
15.33M
Avg. vol.
22.49K
Volume
4.78K
P/E ratio
0.08
52-wk high
$9.70
52-wk low
$3.72
EPS
$45.30
Beta
1.08
Shares outstanding
4.05M
No. of employees
34
News stories
From web sources and news partners
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees34
FoundedJan 1, 1993
HeadquartersSan Francisco, California, United States
SectorBiotechnology
Industry-
Websitekyntrabio.com
Analyst ratings
Based on 5 analysts giving stock ratings to KYNB in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for KYNB in the last 3 months.
Highest
Current $3.79
$43.00 (+1,035.76%)
Average
$38.50 (+916.90%)
Lowest
$35.00 (+824.46%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Okunewitch
Maxim Group
Buy
Initiated
$35.00
+824.5%
10/13/2026
Matthew Keller
H.C. Wainwright
Buy
Reiterated
$43.00
+1,035.8%
10/05/2026
Daniel Brims
Lake Street
Buy
Initiated
$41.00
+982.9%
09/17/2026
Andy Hsieh
William Blair
Hold
Reiterated
-
-
08/31/2026
Jay Olson
Oppenheimer
Buy
Maintained
$35.00
+824.5%
08/14/2026
Michael King
Rodman & Renshaw
Buy
Initiated
$30.00
+692.4%
06/09/2026
Next call in 4 days
Tue, Nov 10, 12:00 AM
Fiscal period
Q3 2026
- / -$3.34
Revenue / Est. (USD)
- / 1.72M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.08M
1.28M
3.74M
-1.47M
Cost of goods sold
1.15M
7.55M
11.67M
6.82M
Cost of revenue
1.15M
7.55M
11.67M
6.82M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.30M
7.25M
5.86M
9.27M
Operating expense
5.30M
7.25M
5.86M
9.27M
Total operating expenses
6.45M
14.80M
17.53M
16.09M
Operating income
-5.37M
-13.52M
-13.80M
-17.56M
Other non operating income
-
-
-
-
EBT including unusual items
-13.15M
-14.61M
-15.13M
11.97M
EBT excluding unusual items
-6.52M
-14.62M
-15.11M
-18.96M
Income tax expense
-
-
-
-1.00K
Effective tax rate
-
-
-
-0.01%
Other operating expenses
-
-
-
-
Net income
200.64M
-14.22M
-15.20M
11.97M
Net profit margin
18,646.47%
-1,113.55%
-406.58%
-812.35%
Earnings per share
49.61
-3.51
-3.76
-4.69
Interest and investment income
931.00K
1.32M
1.11M
975.00K
Interest expense
-2.08M
-2.41M
-2.43M
-2.37M
Net interest expenses
-1.15M
-1.10M
-1.31M
-1.39M
Depreciation and amortization charges
-
-
-
-
EBITDA
-5.18M
-13.51M
-13.79M
-17.56M
Gain or loss from assets sale
-52.16M
52.16M
66.00K
-30.94M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps